Large gap with delayed quotes
|
Last quote
07/03/2025
-
16:42:32
|
Bid
07/03/2025 -
16:47:01
|
Bid Volume |
Ask
07/03/2025 -
16:47:01
|
Ask Volume |
|---|---|---|---|---|
|
109.57
-0.35
(
-0.32% )
|
109.47
|
300 |
109.69
|
100 |
Analysis date: 01.07.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 03.06.2025.
Interest
Very weak
Very weak
One star since 17.06.2025.
Earnings Rev Trend
-0.10
-0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is negative since 28.02.2025 at a price of 143.53.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded below its moving average since 06.05.2025.
4wk Rel Perf
-3.35%
-3.35%
The four-week dividend-adjusted underperformance versus SP500 is 3.35%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 03.06.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.18%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.39%.
Mkt Cap in $bn
6.42
6.42
With a market capitalization between $2 & $8bn, JAZZ PHARMACEUTICALS is considered a mid-cap stock.
G/PE Ratio
12.80
12.80
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
5.21
5.21
The estimated PE is for the year 2027.
LT Growth
66.68%
66.68%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
14
14
Over the last seven weeks, an average of 14 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
83
83
For 1% of index variation, the stock varies on average by 0.83%.
Correlation
0.45
0.45
44.88% of stock movements are explained by index variations.
Value at Risk
33.30
33.30
The value at risk is estimated at USD 33.30. The risk is therefore 30.43%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
06.04.2011
06.04.2011